Search

QL1706

QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

Navafenterol

Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

ATB-346

ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).

Rose bengal

The clinical applications of rose bengal as injectable formulation under the name PV-10 in melanoma, breast cancer and skin conditions such as eczema and psoriasis are being investigated in clinical trials

Bremelanotide

[L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

Carotuximab

NGX267

NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

Oliceridine

Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...

Ferumoxytol

[L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively

Potassium bitartrate

Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732